Winship Cancer Institute, Emory University
Welcome,         Profile    Billing    Logout  
 207 Trials 
1041 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Flowers, Christopher
LEO, NCT02736357: The Lymphoma Epidemiology of Outcomes () Cohort Study

Withdrawn
N/A
12900
US
Mayo Clinic, Emory University, University of Iowa, M.D. Anderson Cancer Center, Washington University School of Medicine, University of Rochester, Weill Medical College of Cornell University, University of Miami
Non-Hodgkin Lymphoma
04/23
04/23
NCT05676450: Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas

Recruiting
N/A
517
US
cell-free DNA
M.D. Anderson Cancer Center
Lymphoma
08/26
08/26
NCT06668376: A Randomized Prospective Study to Evaluate the Incrediwear Products Immediately After ACL Repair

Enrolling by invitation
N/A
90
US
Leg Sleeve, Placebo
Texas Bone and Joint, INCREDIWEAR HOLDINGS, INC., Medical City Denton
Anterior Cruciate Ligament Tear, Medial Collateral Ligament
10/26
11/26
NCT06669741: Clinical Outcomes Related to Arthroscopic Rotator Cuff Repair Recovery Using Incrediwear

Not yet recruiting
N/A
140
US
Placebo, Shoulder Sleeve
Texas Bone and Joint, INCREDIWEAR HOLDINGS, INC., Medical City Denton
Rotator Cuff Tears, Rotator Cuff Injuries, Rotator Cuff Arthropathy of Left Shoulder (Disorder), Rotator Cuff Arthropathy of Right Shoulder (Disorder), Rotator Cuff Arthropathy of Bilateral Shoulders
12/26
12/26
Blum, William
A041703, NCT03739814: Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Recruiting
2
64
US
Blinatumomab, AMG 103, AMG-103, AMG103, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Blincyto, MEDI 538, MEDI-538, MEDI538, MT 103, MT-103, MT103, Inotuzumab Ozogamicin, Besponsa, CMC 544, CMC-544, CMC544, Way 207294, WAY-207294
National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
02/25
02/25
ARTEMIS, NCT04511130: Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant

Completed
2
47
US
MT-401, zedenoleucel
Marker Therapeutics, Inc.
Acute Myeloid Leukemia, Stem Cell Transplantation
03/24
03/24
NCT05303792: Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults with B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma

Recruiting
2
66
US
Cyclophosphamide, Vincristine, Dexamethasone, Inotuzumab Ozogamicin, Methotrexate, Cytarabine, Methylprednisolone, Rituximab, Prednisone, Mercaptopurine, Doxorubicin
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
05/26
05/28
Beat AML, NCT03013998: Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Hourglass Jan 2023 - Mar 2023 : Data from Beat AML trial for acute myeloid leukemia
Recruiting
1/2
2000
US
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Enasidenib, Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), GS-9973, ENTO, Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), TAK-924, MLN4924, Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21)
Beat AML, LLC
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
12/26
12/26
NCT04764474: A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH

Recruiting
1
75
Europe, US
HMPL-306
Hutchmed
Isocitrate Dehydrogenase Gene Mutation
09/24
06/25
IO-202-CL-001, NCT04372433: IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

Active, not recruiting
1
106
US
IO-202, IO-202 and Azacitidine, IO-202 and AZA, IO-202 and Azacitidine + Venetoclax, IO-202 and AZA + Ven
Immune-Onc Therapeutics, California Institute for Regenerative Medicine (CIRM)
AML With Monocytic Differentiation, CMML
01/26
01/27
NCT06226571: A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

Recruiting
1
76
US
SNDX-5613, Chemotherapy Regimen, HiDAC
Syndax Pharmaceuticals
Acute Myeloid Leukemias
02/27
02/27
NKX101-101, NCT04623944: NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

Active, not recruiting
1
61
US
NKX101 - CAR NK cell therapy, Cyclophosphamide, Fludarabine, Cytarabine (ara-C), Decitabine
Nkarta, Inc.
Relapsed/Refractory AML, AML, Adult, MDS, Refractory Myelodysplastic Syndromes
10/24
07/39
NCT04872478: Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL

Recruiting
1
50
US
MRX-2843
Meryx, Inc.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
07/24
12/24
CLN-049-001, NCT05143996: CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Recruiting
1
60
US
CLN-049
Cullinan Oncology Inc.
Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
08/25
11/25
Lonial, Sagar
NCT01169337: Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Checkmark ECOG E3A06 study
Oct 2018 - Oct 2018: ECOG E3A06 study
Active, not recruiting
3
226
Europe, US
Clinical Observation, observation, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid, Quality-of-Life Assessment, Quality of Life Assessment
National Cancer Institute (NCI)
Light Chain Deposition Disease, Smoldering Multiple Myeloma
01/19
03/25
NCT05172596 / 2021-003747-22: PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma

Active, not recruiting
2
146
Europe, Canada, Japan, US, RoW
PHE885
Novartis Pharmaceuticals, Novartis Pharma AG
Multiple Myeloma
02/25
02/25
NCT04776018: A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

Terminated
1/2
27
Canada, US
TAK-981, Mezagitamab, Daratumumab and Hyaluronidase-fihj
Takeda
Relapsed and/or Refractory Multiple Myeloma (RRMM)
08/23
11/23
CFT7455-1101, NCT04756726: Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Recruiting
1/2
224
US
cemsidomide, CFT7455, Dexamethasone Oral
C4 Therapeutics, Inc.
Multiple Myeloma, Lymphoma, Non-Hodgkin's
09/25
12/25
NCT04887259 / 2020-004583-26: Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

Checkmark Safety data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Dec 2022 - Dec 2022: Safety data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Checkmark Efficacy data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Dec 2022 - Dec 2022: Efficacy data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Checkmark First patient dosing for P1/2a for relapsed refractory CLL
More
Terminated
1
16
Europe, US
LAVA-051, Interleukin 2
Lava Therapeutics, LAVA Therapeutics N.V., LAVA Therapeutics B.V.
Chronic Lymphocytic Leukemia, Multiple Myeloma, Acute Myeloid Leukemia
09/23
09/23
KTX-MMSET-001, NCT05651932: A Study of an MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma

Recruiting
1
125
Europe, Canada, US
Cohort A1 & A2, KTX-1001, Dexamethasone, Cohort C1 & C2, Carfilzomib, Cohort D, Pomalidomide
K36 Therapeutics, Inc.
Multiple Myeloma, Myeloma, Myeloma Multiple
12/25
06/26
Berman, Jonathan
VT3996-201, NCT03397706: Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies

Completed
1/2
64
US, RoW
VRx-3996, Nanatinostat, Valganciclovir
Viracta Therapeutics, Inc.
Epstein-Barr Virus Associated Lymphoma, Lymphoproliferative Disorders
04/23
05/23
NCT03088878: A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

Completed
1/2
102
US
Cirmtuzumab (2-16 kg/mg) plus Ibrutinib, UC-961, Imbruvica, Cirmtuzumab (300mg) plus Ibrutinib, Cirmtuzumab (600 mg) plus ibrutinib, Cirmtuzumab (RDR) plus ibrutinib, Cirmtuzumab plus ibrutinib, Ibrutinib alone
Oncternal Therapeutics, Inc, California Institute for Regenerative Medicine (CIRM), University of California, San Diego, Pharmacyclics LLC.
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
09/24
09/24
Arellano, Martha
APTIVATE, NCT03850574: Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1/2
240
Europe, US, RoW
Tuspetinib, HM43239, Venetoclax Oral Tablet, Venetoclax, Azacitidine for Intravenous Infusion, Azacitidine
Aptose Biosciences Inc.
Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome with Excess Blasts-2, Chronic Myelomonocytic Leukemia
11/26
04/27
FELIX, NCT04404660: A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Hourglass Jul 2024 - Dec 2024 : Submission in UK for adult r/r B-ALL
Active, not recruiting
1/2
153
NA
AUTO1, Obecabtagene autoleucel (obe-cel)
Autolus Limited
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
05/25
05/25
NCT04611256: Mesenchymal Stem Cells in Patients Diagnosed With COVID-19

Recruiting
1
20
RoW
MSC, Control
Hospital Reg. Lic. Adolfo Lopez Mateos, Instituto de Terapia Celular: ITC
Covid19
11/20
12/20
NCT04619290: Outpatient Treatment With CoVid-19 With Prexablu

Recruiting
1
46
RoW
Sublingual Methylene blue, Control patients
Hospital Reg. Lic. Adolfo Lopez Mateos
Sars Cov 2
11/20
12/20
NCT05918913: Expanded Access Program for Revumenib

Available
N/A
US
Revumenib, SNDX-5613
Syndax Pharmaceuticals
Relapsed/Refractory Acute Leukemia
 
 
SCOPE-L, NCT05237258: Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Recruiting
N/A
2300
US
Specialty Palliative Care, Primary Palliative Care
Massachusetts General Hospital, Patient-Centered Outcomes Research Institute
Relapsed Adult AML, Primary Refractory Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia
04/28
04/29
Klisovic, Rebecca
NCT04530565: Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Recruiting
3
348
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Blinatumomab, AMG 103, AMG-103, AMG103, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Blincyto, MEDI 538, MEDI-538, MEDI538, MT 103, MT-103, MT103, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Dasatinib, BMS 354825, BMS-354825, BMS354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, LenaDex, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Echocardiography, EC, Electrocardiography, ECG, EKG, Lumbar Puncture, LP, Spinal Tap, Mesna, 2-Mercaptoethanesulfonate, Sodium Salt, Ausobronc, D-7093, Filesna, Mercaptoethane Sulfonate, Mercaptoethanesulfonate, Mesnex, Mesnil, Mesnum, Mexan, Mistabron, Mistabronco, Mitexan, Mucofluid, Mucolene, UCB 3983, Uromitexan, Ziken, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Jylamvo, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, MUGA, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Ponatinib Hydrochloride, AP24534 HCl, Iclusig, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
07/28
07/28
NCT03610971: Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

Recruiting
2
41
US
Ruxolitinib, Jakafi®, BCR-ABL Tyrosine Kinase Inhibitor (TKI), TKI
H. Lee Moffitt Cancer Center and Research Institute, H. Jean Khoury Cure CML Consortium, Incyte Corporation
Chronic Phase Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, Chronic Phase
12/25
12/26
Hill, Brian
EA4151, NCT03267433: Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Active, not recruiting
3
689
US, RoW
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous, Autologous Hematopoietic Cell Transplantation, Autologous Stem Cell Transplant, Autologous Stem Cell Transplantation, Stem Cell Transplantation, Autologous, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspirate, BONE MARROW, LIQUID, Human Bone Marrow Aspirate, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Rituximab, ABP 798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima, Rituximab and Hyaluronidase Human, Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Mantle Cell Lymphoma
01/27
01/27
EVOLVE CLL/SLL, NCT04269902: Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), Study

Recruiting
3
247
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA 101, GA-101, GA101, Gazyva, huMAB(CD20), R 7159, R-7159, R7159, RO 5072759, RO-5072759, RO5072759, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Venetoclax, ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
10/28
10/28
NCT02073097: Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma

Completed
1/2
48
US
Carfilzomib, Kyprolis, PR-171, Rituximab, IDEC-C2B8, IDEC-C2B8 monoclonal antibody, Mabthera, MOAB IDEC-C2B8, Rituxan, Cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, Doxorubicin hydrochloride, ADM, ADR, Adria, Adriamycin PFS, Adriamycin RDF, Vincristine sulfate, leurocristine sulfate, VCR, Vincasar PFS, Prednisone, DeCortin, Deltra, Pegfilgrastim, Neulasta, Recombinant methionyl human granulocyte colony-stimulating factor (G-CSF), Acyclovir, Zovirax
Case Comprehensive Cancer Center
Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma
07/21
06/23
NKX019-101, NCT05020678: NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

Active, not recruiting
1
150
US, RoW
NKX019
Nkarta, Inc.
Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma, Large-cell Lymphoma
03/25
12/38
NCT05053659: Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma

Recruiting
1
36
US
Loncastuximab tesirine, ADCT-402, lonca, Venetoclax, ABT-199, GDC-0199
Paolo Caimi, MD
Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
06/25
12/25
Kalinsky, Kevin
RxPONDER, NCT01272037: Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive Breast Cancer

Active, not recruiting
3
5018
Europe, Canada, US, RoW
Anastrozole, Anastrazole, Arimidex, ICI D1033, ICI-D1033, ZD-1033, Exemestane, Aromasin, FCE-24304, Laboratory Biomarker Analysis, Letrozole, CGS 20267, CGS-20267, CGS20267, Femara, Fempro, Quality-of-Life Assessment, Quality of Life Assessment, Systemic Chemotherapy, Tamoxifen Citrate, Apo-Tamox, Clonoxifen, Dignotamoxi, Ebefen, Emblon, Estroxyn, Fentamox, Gen-Tamoxifen, Genox, ICI 46,474, ICI 46474, ICI-46474, ICI46474, Jenoxifen, Kessar, Ledertam, Lesporene, Nolgen, Noltam, Nolvadex, Nolvadex-D, Nourytam, Novo-Tamoxifen, Novofen, Noxitem, Oestrifen, Oncotam, PMS-Tamoxifen, Soltamox, TAM, Tamax, Tamaxin, Tamifen, Tamizam, Tamofen, Tamoxasta, Tamoxifeni Citras, Zemide
National Cancer Institute (NCI)
Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma
02/23
10/32
postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting
3
368
Europe, US, RoW
Abemaciclib, Fulvestrant, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasm, Neoplasm Metastasis
02/24
02/26
SWOG-S1501, NCT03418961: S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer

Recruiting
3
817
US, RoW
Carvedilol, Coreg, Laboratory Biomarker Analysis, Patient Observation, Active Surveillance, deferred therapy, expectant management, observation, Watchful Waiting
SWOG Cancer Research Network, National Cancer Institute (NCI)
Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
01/30
01/30
OFSET, NCT05879926: Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Recruiting
3
3960
Canada, US
Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression
NRG Oncology, National Cancer Institute (NCI)
Breast Cancer
01/32
07/34
EAY131-Z1K, NCT06400251: Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)

Active, not recruiting
2
35
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipatasertib, GDC 0068, GDC-0068, GDC0068, RG 7440, RG-7440, RG7440, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
03/25
03/25
EAY131-Y, NCT04439123: Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

Active, not recruiting
2
35
US
Capivasertib, AZD 5363, AZD-5363, AZD5363, Truqap
National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
11/19
03/25
SERIES, NCT06263543: Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC

Recruiting
2
75
US
Sacituzumab govitecan, Trodelvy
Reshma L. Mahtani, D.O., Gilead Sciences
Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Low Breast Cancer
06/26
12/26
NCT04266249: CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Recruiting
2
2156
US
Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Lumpectomy, Lumpectomy of Breast, Partial Mastectomy, Mastectomy, Mammectomy, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, protein-bound paclitaxel, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pertuzumab, 2C4, 2C4 Antibody, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, rhuMAb2C4, RO4368451, Radiation Therapy, Cancer Radiotherapy, Irradiate, irradiated, irradiation, RADIATION, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar SB3, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-QYYP, Trazimera, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
10/26
12/38
VICC-NCBRE23172, NCT05919108: Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Recruiting
2
30
US
Endocrine Therapy, Biopsy of breast, Neratinib, Biospecimen Collection, Mammogram, Magnetic Resonance Imaging, Breast Surgery, Ultrasound
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI), Puma Biotechnology, Inc.
Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer, Anatomic Stage III Breast Cancer, Invasive Breast Lobular Carcinoma
04/30
04/31
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Hourglass Jan 2023 - Dec 2023 : From P2 I-SPY 2 trial for invasive breast cancer
Checkmark Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Checkmark Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
Nov 2018 - Nov 2018: Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
More
Recruiting
2
5000
US
Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel
QuantumLeap Healthcare Collaborative
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/30
12/31
NCT04946864: A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer

Suspended
1/2
65
US, RoW
APG-2575, APG2575, Palbociclib
Ascentage Pharma Group Inc.
Breast Cancer, Solid Tumor, Adult
08/24
10/24
NCT06460298: ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Recruiting
1/2
51
US
ProAgio Dose Levels (DL) 1,2,3,4, ACT50, Gemcitabine, ProAgio Dose Expansion
ProDa BioTech, LLC, Emory University, Georgia State University
Triple Negative Breast Cancer
07/26
10/26
INX-315-01, NCT05735080: Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Recruiting
1/2
90
US, RoW
INX-315, Fulvestrant, faslodex
Incyclix Bio
Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Ovarian Cancer, CCNE1 Amplification, Solid Tumor, Advanced Cancer, Metastatic Cancer
12/25
06/26
NCT05304962: FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

Recruiting
1
64
US
RGT-419B, RGT-419B in combination with hormonal therapy
Regor Pharmaceuticals Inc.
Breast Cancer
12/25
09/26
NCT05377996: A Study of XMT-1660 in Participants With Solid Tumors

Hourglass Jul 2024 - Dec 2024 : Initial dose escalation and backfill cohort data for solid tumors
Recruiting
1
319
US
XMT-1660
Mersana Therapeutics
Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma
12/26
05/27
KEYNOTE-F86, NCT05787587: A Study of PARG Inhibitor IDE161 in Participants with Advanced Solid Tumors

Recruiting
1
216
US
IDE-161, Pembrolizumab, KEYTRUDA®
IDEAYA Biosciences, Merck Sharp & Dohme LLC
Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers
10/26
05/27
Kaufman, Jonathan
iinnovate-1, NCT03215030 / 2021-006038-37: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Completed
1/2
272
Europe, Canada, Japan, US, RoW
Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
07/24
11/24
NCT04123418: A Study of WVT078 in Patients With Multiple Myeloma (MM)

Terminated
1
56
Europe, Japan, US, RoW
WVT078, WHG626
Novartis Pharmaceuticals
Multiple Myeloma (MM)
12/24
12/24
NCT05391750: Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

Recruiting
1
72
US
Tocilizumab, Actemra, Immunoglobulin G1, Anti-(Human Interleukin 6 Receptor) (Human-Mouse Monoclonal MRA Heavy Chain), Disulfide with Human-Mouse Monoclonal MRA Kappa-Chain, Dimer, MRA, R-1569, RoActemra, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
Emory University, National Cancer Institute (NCI)
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
02/26
02/27
NPC-QIC, NCT02852031: National Collaborative to Improve Care of Children With Complex Congenital Heart Disease

Recruiting
N/A
1000
Europe, Canada, US
Collaborative Learning Network
Children's Hospital Medical Center, Cincinnati
Hypoplastic Left Heart Syndrome (HLHS)
05/26
05/28
Investigator, Principal
OCEAN, NCT04986982 / 2020-001175-32: OpiCapone Effect on Motor Fluctuations and pAiN

Completed
4
144
Europe
Opicapone 50 mg, BIA 9-1067, Placebo
Bial - Portela C S.A., Bial - Portela & Ca, S.A.
Parkinson Disease
02/24
02/24
NCT04248205: Ketamine for Post-operative Analgesia in Hemorrhoidectomy

Recruiting
4
100
US
Ketamine
University of Oklahoma
Hemorrhoids
01/25
07/25
NCT05400369: A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Completed
4
140
RoW
Sitafloxacin, Gracevit, Moxifloxacin Hydrochloride, Avelox
Daiichi Sankyo
COPD Exacerbation Acute
09/24
09/24
TrEAT_TD2, NCT05677282: Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, with Loperamide Adjunct

Recruiting
4
150
RoW
Rifaximin 550 MG, Azithromycin 500 MG, Loperamide
Henry M. Jackson Foundation for the Advancement of Military Medicine, Infectious Diseases Clinical Research Program, Uniformed Services University of the Health Sciences
Diarrhoea;Acute, Diarrhea Travelers
09/25
12/25
NCT06397781: Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients

Not yet recruiting
4
100
US
Skin Cleanser Combination No.1
Boston Children's Hospital
Atopic Dermatitis
12/28
12/28
NCT06793358: Use of Remimazolam and Fentanyl for Procedural Sedation in Patients Undergoing Dental Extraction

Not yet recruiting
4
40
US
fentanyl and Remimazolam
Indiana University, Indiana University Health
Dental Extraction
01/26
03/26
POUR, NCT04994431: Post-Operative Urinary Retention () in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin

Terminated
4
109
US
Tamsulosin Hydrochloride
University of Massachusetts, Worcester, UMass Memorial Health Care
Thoracic Diseases, Urinary Retention
10/23
10/23
NCT02932410 / 2016-001062-28: A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

Active, not recruiting
3
165
Europe, Canada, US, RoW
Macitentan, ACT-064992, Standard-of-care
Actelion
Pulmonary Arterial Hypertension
08/24
07/25
TROPION-LUNG01, NCT04656652 / 2020-004643-80: Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations

Hourglass Jul 2023 - Dec 2023 : Acceptance of regulatory submission for 2L+ NSCLC with or without actionable genomic alterations (based on TROPION-Lung01 trial)
Apr 2023 - Jun 2023: Topline results from TROPION-LUNG01 trial for metastatic NSCLC
Active, not recruiting
3
590
Europe, Canada, Japan, US, RoW
DS-1062a, Datopotamab deruxtecan (Dato-DXd), Docetaxel
Daiichi Sankyo, AstraZeneca
Non-small Cell Lung Cancer
05/24
06/25
IDeate-Lung02, NCT06203210: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Recruiting
3
540
Europe, Canada, Japan, US, RoW
Ifinatamab deruxtecan, I-DXd, Topotecan, Amrubicin, Lurbinectedin
Daiichi Sankyo, Merck Sharp & Dohme LLC
Small Cell Lung Cancer
04/27
02/29
TNX-N, NCT03503136: Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC

Not yet recruiting
3
632
RoW
docetaxel, nedaplatin, and capecitabine, TNX induction chemotherapy, nedaplatin, N, docetaxel, cisplatin, and fluorouracil, TPF induction chemotherapy, cisplatin, P, docetaxel, cisplatin, and capecitabine, TPX induction chemotherapy, docetaxel, nedaplatin, and fluorouracil, TNF induction chemotherapy
Sun Yat-sen University, Tongji Hospital, Wuhan Union Hospital, China, Peking University, Air Force Military Medical University, China, Second Affiliated Hospital of Soochow University, The First Affiliated Hospital of Guangdong Pharmaceutical University, First People's Hospital of Foshan, Fifth Affiliated Hospital, Sun Yat-Sen University, Cancer Hospital of Guizhou Province, Xiangya Hospital of Central South University, Jilin Provincial Tumor Hospital, Henan Cancer Hospital, Hunan Cancer Hospital, Cancer Hospital of Guangxi Medical University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
06/24
06/26
NCT05839899: Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location

Recruiting
3
50
US
Mifepristone plus one dose Misoprostol, Mifepristone plus two doses Misoprostol
Planned Parenthood League of Massachusetts
Abortion
07/24
09/24
HERTHENA-Lung02, NCT05338970 / 2021-005879-40: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Active, not recruiting
3
586
Europe, Canada, Japan, US, RoW
Patritumab Deruxtecan, HER3-DXd, U3-1402, Platinum-based chemotherapy
Daiichi Sankyo, Merck Sharp & Dohme LLC
Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
05/24
06/26
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy

Recruiting
3
102
Europe, Canada, US, RoW
Ampreloxetine, TD-9855, Placebo
Theravance Biopharma
Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
12/24
01/27
NCT06672016: Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential

Not yet recruiting
3
1500
US
Transdermal system containing progestin
Mylan Pharmaceuticals Inc
Female Contraception
03/27
04/27
VDJ001-RA-Ⅲ, NCT06726096: Phase III Trial of VDJ001 in Patients with Moderate-to-severe Active Rheumatoid Arthritis

Not yet recruiting
3
615
RoW
Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection
Beijing VDJBio Co., LTD.
Rheumatoid Arthritis (RA)
12/25
12/26
LIBERTY, NCT06716814: Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa

Not yet recruiting
3
78
Europe
Efanesoctocog alfa, BIVV001, Altuvoct, Altuviiio, Recombinant coagulation factor VIII Fc-von-Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)
Swedish Orphan Biovitrum, PSI CRO
Severe Haemophilia A
08/26
08/26
frontMIND, NCT04824092 / 2020-002990-84: Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

Calendar Jul 2025 - Dec 2025: Primary analysis data from frontMIND trial in combination with Revlimid for newly diagnosed DLBCL
Hourglass Jun 2021 - Jun 2021 : Updated data from frontMIND trial for newly diagnosed DLBCL at EHA 2021
Hourglass Jun 2021 - Jun 2021 : Updated data from frontMIND trial for newly diagnosed DLBCL at ASCO 2021
Active, not recruiting
3
899
Europe, Canada, Japan, US, RoW
Tafasitamab, Monjuvi, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo
Incyte Corporation
Diffuse Large B-cell Lymphoma
06/25
05/26
StrataSTEPS, NCT05517902: StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects

Completed
3
1
US
StrataGraft
Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority
Skin Wound, Burns, Trauma-related Wound
05/24
05/24
DESTINY-Gastric04, NCT04704934 / 2020-004559-34: Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen

Jan 2024 - Dec 2024: Data from DESTINY-Gastric04 trial for HER2+ve gastric cancer
Jan 2024 - Dec 2024: Acceptance of regulatory submission for HER2 positive metastatic and/or unresectable gastric or gastroesophageal junction adenocarcinoma (based on DESTINY-Gastric04 trial)
Checkmark Data from DESTINY-Gastric04 trial for HER2 Positive Gastric Cancer (GC) or GEJ at ESMO 2021
Jul 2021 - Jul 2021: Data from DESTINY-Gastric04 trial for HER2 Positive Gastric Cancer (GC) or GEJ at ESMO 2021
Checkmark First patient was dosed in DESTINY-Gastric04 in patients with HER2 positive gastric or GEJ adenocarcinoma
More
Active, not recruiting
3
490
Europe, Japan, RoW
Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel
Daiichi Sankyo, AstraZeneca
Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
10/25
02/26
NCT05847348: 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients

Recruiting
3
110
RoW
68Ga-PSMA-11, Illucix, gallium Ga 68 Gozetotide, PET/CT or PET/MRI, Imaging by PET
Telix Pharmaceuticals (Innovations) Pty Limited, Grand Pharmaceutical (China) Co., Ltd.
Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma
12/25
07/26
DESTINY-Breast05, NCT04622319 / 2020-003982-20: A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy

Jan 2024 - Dec 2024: Acceptance of of regulatory submission for HER2+ post neo-adjuvant breast cancer (DESTINY-Breast05 trial)
Jan 2024 - Dec 2024: Data from DESTINY-Breast05 trial for HER2+ post neo-adjuvant breast cancer
Active, not recruiting
3
1600
Europe, Canada, Japan, US, RoW
DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1)
Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI)
HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
12/25
12/30
FREEDOM, NCT05817812: A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa

Active, not recruiting
3
93
Europe, RoW
Efanesoctocog alfa, BIVV001
Swedish Orphan Biovitrum, Syneos Health
Hemophilia A, Severe
05/26
05/26
TROPION-Lung07, NCT05555732: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer

Recruiting
3
1170
Europe, Canada, Japan, US, RoW
Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA®, Pemetrexed, Alimta, Pemfexy, Carboplatin, Cisplatin
Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC
Metastatic Non Small Cell Lung Cancer
08/27
08/27
DESTINY-Breast15, NCT05950945: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

Recruiting
3
250
Europe, US, RoW
Trastuzumab Deruxtecan, T-DXd, DS-8201a (trastuzumab derextecan), Enhertu®
Daiichi Sankyo, AstraZeneca
Breast Cancer
10/27
10/27
Tropion-Lung08, NCT05215340 / 2021-002555-10: Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

Jan 2024 - Dec 2024: Data from TROPION-Lung08 trial for advanced or metastatic NSCLC
Jan 2024 - Dec 2024: Acceptance of regulatory submission for 1L metastatic NSCLC (based on TROPION Lung08 trial)
Recruiting
3
740
Europe, Canada, Japan, US, RoW
Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA®
Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC
Metastatic Non Small Cell Lung Cancer
02/28
04/28
ARTEMIS, NCT04797884: Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma

Recruiting
2/3
166
US
TheraBionic Device, Placebo Device, Quality of Life Assessment
THERABIONIC INC., National Cancer Institute (NCI)
Hepatocellular Carcinoma
10/24
10/24
FORTIFI-HN01, NCT06788990: a Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Recruiting
2/3
650
US
Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo
Bicara Therapeutics
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
04/28
07/29
TRIPHASE, NCT06101745: Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery

Recruiting
2/3
336
Europe
Nizaracianine Triflutate, ZW800-1, Placebo Comparator, Sugar
Curadel Surgical Innovations, Inc., Leiden University Medical Center, Erasmus Medical Center
Injury of Ureter During Surgery (Disorder)
10/25
11/25
ESTRELLA, NCT04764448 / 2020-003313-35: A Study of Belcesiran in Patients With AATLD

Terminated
2
16
Europe, Canada, US, RoW
Belcesiran, Placebo
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Alpha 1-Antitrypsin Deficiency
12/23
05/24
AAVIATE, NCT04514653: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Recruiting
2
115
US
Ranibizumab, RGX-314 Dose 1, Combination Product, RGX-314 Dose 2, RGX-314 Dose 3, Local Steroid, Topical Steroid
AbbVie, AbbVie
Neovascular Age-Related Macular Degeneration (nAMD)
10/25
08/26
RGX-314-2103, NCT04832724: RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)

Completed
2
60
US
RGX-314
AbbVie
Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration
10/23
03/24
Orchid 1, NCT06132919: Efficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS)

Recruiting
2
40
Europe
MC2-25 cream, MC2-25 vehicle
MC2 Therapeutics
Vulvar Lichen Sclerosus
11/24
11/24
StrataSOMA, NCT04765202: StrataGraft Overlay of Meshed Autograft in Full-thickness Thermal Burns

Completed
2
13
US
AG Tx, Meshed Autograft, SOMA Tx, StrataGraft skin tissue Overlay of Meshed Autograft (SOMA)
Stratatech, a Mallinckrodt Company
Full Thickness Thermal Burn
03/24
03/24
HERTHENA-PanTumor01, NCT06172478: A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Recruiting
2
400
Europe, Japan, US, RoW
HER3-DXd, Patritumab Deruxtecan, U3-1402
Daiichi Sankyo, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer
06/25
04/26
NCT05198310 / 2022-000169-42: Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor

Completed
2
145
Europe, US, RoW
KPL-404, abiprubart, Placebo
Kiniksa Pharmaceuticals, Ltd., Kiniksa Pharmaceuticals, Ltd.
Arthritis, Rheumatoid
02/24
05/24
EAD501, NCT05607615 / 2022-003819-29: A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease

Recruiting
2
90
US
Hydroxypropyl Beta Cyclodextrin, Trappsol Cyclo, Placebo, 0.5N saline
Cyclo Therapeutics, Inc., Cyclo Therapeutics Inc.
Alzheimer's Disease
03/24
03/24
NCT05569252 / 2022-000676-19: A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum

Completed
2
65
Europe, US
DS-1211b, Placebo
Daiichi Sankyo, PXE International
Pseudoxanthoma Elasticum
11/23
11/23
IDeate-PanTumor02, NCT06330064: A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors

Recruiting
2
520
Europe, Japan, US, RoW
Ifinatamab deruxtecan, I-DXd
Daiichi Sankyo, Merck Sharp & Dohme LLC
Recurrent or Metastatic Solid Tumors
07/28
07/28
MAST, NCT06355583: Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant () Trial

Not yet recruiting
2
50
Europe
EBX-102, IMT capsules, Placebo
Imperial College London
Acute Lymphoblastic Leukaemia, Acute Leukemia of Ambiguous Lineage, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia
02/26
05/27
NCT04870905: Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma

Not yet recruiting
2
100
RoW
Tis-U-Sol
Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Union hospital of Fujian Medical University, Zhujiang Hospital, Guangdong Provincial People's Hospital
Nasopharyngeal Neoplasms
05/24
05/26
IDeate-Lung01, NCT05280470 / 2022-000503-13: Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Active, not recruiting
2
187
Europe, Japan, US, RoW
Ifinatamab Deruxtecan (I-DXd), DS-7300a
Daiichi Sankyo, Merck Sharp & Dohme LLC
Extensive-stage Small-cell Lung Cancer
01/25
04/25
SPG302-SCZ-201, NCT06442462: Study of SPG302 in Adults With Schizophrenia

Recruiting
2
32
RoW
SPG302, Placebo
Spinogenix
Schizophrenia
06/25
10/25
CBeyond, NCT06577090: Study to Evaluate the Effect on Obesity of Once Weekly Nimacimab Injection and Once Weekly Nimacimab Injection Co-administered With Semaglutide Injection Versus Placebo

Recruiting
2
120
US
Nimacimab injection, Nimacimab placebo injection, semaglutide injection
Skye Bioscience, Inc., Bird Rock Bio Sub, Inc.
Obesity
08/25
01/26
NCT05029336: Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases

Recruiting
2
20
US
Depletion of CD3/CD19 in an autologous stem cell transplant, CD3/CD19 depletion using cliniMACs device
Stephan Grupp MD PhD
Systemic Lupus Erythematosus, Systemic Sclerosis
12/26
05/31
 

Download Options